ArticleJournal of virology2025
VCY mediates inhibition of PFV replication via interaction with the transcription activator Tas.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prototype foamy viruses (PFVs) are complex retroviruses that establish long-term latent infections in hosts without causing disease, positioning them as potential safe gene transfer vectors. Understanding the host proteins involved in PFV replication and their interaction mechanisms may enhance gene transfer efficiency. However, only a few cellular proteins are known to influence PFV replication. In this study, transcriptomic analysis of PFV-infected HT1080 cells revealed significant downregulation of variable charge Y (VCY) mRNA, indicating its potential significance in regulating PFV replication. Overexpression of VCY significantly inhibits PFV replication, whereas VCY knockdown enhances viral replication, which can be reversed by reintroducing the VCY protein. VCY interacted with the Tas DNA-binding and transcriptional activation domains and interfered with its binding to the PFV long terminal repeat and internal promoter, inhibiting the transactivation function of Tas. The N-terminal region of VCY, which contains a nuclear localization signal, is essential for this function. Additionally, VCY suppresses bovine foamy virus (BFV) replication by impairing the transactivation activity of BFV Tas, suggesting a broad-spectrum inhibitory effect on FV replication. Collectively, our data elucidate the role of VCY in inhibiting PFV replication through transcriptional interference for the first time, providing valuable insights into viral latency and host interactions.IMPORTANCEFVs can integrate into host chromosomes and are nonpathogenic in natural hosts or experimentally infected animals, making them safe and efficient gene transfer vectors. They establish lifelong latent infections without evident pathology in the host. To date, only a few host factors have been identified that affect PFV replication. In this study, we report that VCY inhibits PFV replication by modulating the function of the transcription activator Tas. Currently, there have been no studies examining the relationship between VCY and viruses, making this the inaugural report on its association with viral infection. Our data provide important insights into the role of VCY in PFV life cycle, which will aid in understanding the mechanisms underlying retroviral latent infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.